UY27599A1 - DIRECTLY COMPRESSIBLE ACITHROMYCIN FORMULATIONS - Google Patents

DIRECTLY COMPRESSIBLE ACITHROMYCIN FORMULATIONS

Info

Publication number
UY27599A1
UY27599A1 UY27599A UY27599A UY27599A1 UY 27599 A1 UY27599 A1 UY 27599A1 UY 27599 A UY27599 A UY 27599A UY 27599 A UY27599 A UY 27599A UY 27599 A1 UY27599 A1 UY 27599A1
Authority
UY
Uruguay
Prior art keywords
acithromycin
tablet
formulations
mga
pharmaceutically acceptable
Prior art date
Application number
UY27599A
Other languages
Spanish (es)
Inventor
Brendan John Murphy
Steven William Collier
Ernest Shing Quan
Barbara Alice Johnson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Priority to UY27599A priority Critical patent/UY27599A1/en
Publication of UY27599A1 publication Critical patent/UY27599A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una mezcla en seco, utilizada para formar comprimidos de acitromicina por compresión directa, que comprende acitromicina no dihidratada y al menos un excipiente farmacéuticamente aceptable. Esta invención se refiere también a un comprimido de acitromicina que comprende acitromicina no dihidratada y al menos un excipiente farmacéuticamente aceptable. Preferiblemente, el comprimido de acitromicina se forma mediante compresión directa de la mezcla en seco, de la presente invención, para formar dicho comprimido de acitromicina. Preferiblemente, el comprimido de acitromicina, de la presente invención, contiene una dosificación de 250 mgA, 500 mgA ó 600 mgA de acitromicina. Esta invención se refiere además a un comprimido de acitromicina que se produce formando una mezcla en seco de una forma A de acitromicina no granulada, y al menos un excipiente farmacéuticamente aceptable. El comprimido de acitromicina se forma a continuación mediante compresión directa de la mezcla en seco.The present invention relates to a dry mix, used to form acythromycin tablets by direct compression, which comprises undihydrated acithromycin and at least one pharmaceutically acceptable excipient. This invention also relates to an acithromycin tablet comprising undihydrated acithromycin and at least one pharmaceutically acceptable excipient. Preferably, the acithromycin tablet is formed by direct compression of the dry mix of the present invention to form said acithromycin tablet. Preferably, the acithromycin tablet of the present invention contains a dosage of 250 mgA, 500 mgA or 600 mgA of acithromycin. This invention further relates to an acithromycin tablet that is produced by forming a dry mixture of a non-granulated form of acithromycin A, and at least one pharmaceutically acceptable excipient. The acithromycin tablet is then formed by direct compression of the dry mixture.

UY27599A 2002-12-20 2002-12-20 DIRECTLY COMPRESSIBLE ACITHROMYCIN FORMULATIONS UY27599A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UY27599A UY27599A1 (en) 2002-12-20 2002-12-20 DIRECTLY COMPRESSIBLE ACITHROMYCIN FORMULATIONS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UY27599A UY27599A1 (en) 2002-12-20 2002-12-20 DIRECTLY COMPRESSIBLE ACITHROMYCIN FORMULATIONS

Publications (1)

Publication Number Publication Date
UY27599A1 true UY27599A1 (en) 2003-07-31

Family

ID=38812723

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27599A UY27599A1 (en) 2002-12-20 2002-12-20 DIRECTLY COMPRESSIBLE ACITHROMYCIN FORMULATIONS

Country Status (1)

Country Link
UY (1) UY27599A1 (en)

Similar Documents

Publication Publication Date Title
AR037930A1 (en) DIRECTLY COMPRESSIBLE ACITHROMYCIN FORMULATIONS
CY1122259T1 (en) RAPID DISSOLVATION PHARMACEUTICAL FORM CONTAINING SINACALCET HCL
AR036643A1 (en) ORGANIC COMPOUNDS
ECSP088499A (en) NEW COMPOUNDS OF 2-AMINO-IMIDAZOL-4-ONA AND ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR USE IN THE TREATMENT OF COGNITIVE ALTERATION, ALZHEIMER'S DISEASE, NEURODEGENERATION AND DEMENTIA
UY28931A1 (en) USED PIRROLOTRIAZINE DERIVATIVES TO TREAT HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS
MY157661A (en) Bendamustine pharmaceutical compositions
WO2007016563A3 (en) Alcohol resistant pharmaceutical formulations
WO2004000197A3 (en) Quick dissolve compositions and tablets based thereon
CO5190672A1 (en) COMPOSITION FOR ORAL DOSAGE, INSTANT DISSOLUTION
ES2181417T3 (en) FORMULATION OF CAPSULES OR TABLETS OF EFAVIRENZ OF FAST DISSOLUTION USING SUPER-DISINTEGRANTS.
AR034900A1 (en) USE OF AN EFFECTIVE AMOUNT OF A PDE4 INHIBITOR AND AN ANTI-POLINERGIC AGENT, WELL IN COMBINED FORM ONLY OR SEPARATELY, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, METHOD TO PREPARE THEM, AND USE OF A COMPOSITION THAT INCLUDES AN EFFECTIVE AMOUNT OF A PDD AN EFFECTIVE AMOUNT
CO5650230A2 (en) STABLE COMPOSITIONS OF ATORVASTATIN PREPARED WITH GRANULATION IN MOISTURE
AR036085A1 (en) DOSAGE FORMS AND PROCEDURE FOR MANUFACTURING
HUP0100171A2 (en) Use of endothelin receptor antagonists for producing pharmaceutical preparations for combating obesity
BRPI0511305A (en) method of relieving an annular or sarcoid granuloma, manufactured article and use of an lfa-1 antagonist
UY27599A1 (en) DIRECTLY COMPRESSIBLE ACITHROMYCIN FORMULATIONS
CL2004001317A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING THE PROGESTERONE RECEIVER ANTAGONIST 11B- (4-ACETILFENIL) -17B-HIDROXI-17 ALFA- (1,1,2,2,2-PENTAFLUOROETIL) -ESTRA-4,9-DIEN-3-ONA AND A PURE ANTIESTROGEN; AND ITS USE TO TREAT A DEPENDENT DISEASE OF H
AR039162A1 (en) VENLAFAXINA FORMULATIONS OF EXTENDED LIBERATION
PL378106A1 (en) Method for producing a pharmaceutical composition in the form of fibrate-containing tablets and tablets produced by said method
AR099137A2 (en) FORMULATION FOR DIRECT COMPRESSION AND PROCESS
AR030660A1 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF AN ILLNESS ASSOCIATED WITH AN EXCESS OF IL-12 PRODUCTION
BR0206272A (en) Solid unit dosage form comprising citalopram
DE602004022578D1 (en) ANTITUMORAL TERPEN COMPOUNDS
AR021719A1 (en) ANTIESTROGEN ORAL PHARMACEUTICAL COMPOSITION.
PL1626726T3 (en) Use of lornoxicam or lornoxicam analogue compounds

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150126